Cargando…
Evaluating tofacitinib citrate in the treatment of moderate-to-severe active ulcerative colitis: design, development and positioning of therapy
The etiology of ulcerative colitis (UC) is complex and involves a host of genetic, epigenetic and environmental factors. Over the last thirty years, signaling pathways like the Janus kinase (JAK) signaling pathway have been implicated in its pathogenesis. Pharmacologic blockade of this pathway is av...
Autores principales: | Tran, Vivy, Shammas, Rania M, Sauk, Jenny S, Padua, David |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6507103/ https://www.ncbi.nlm.nih.gov/pubmed/31118734 http://dx.doi.org/10.2147/CEG.S150908 |
Ejemplares similares
-
Population Pharmacokinetics of Tofacitinib in Patients With Moderate to Severe Ulcerative Colitis
por: Vong, Camille, et al.
Publicado: (2021) -
Initial experience of tofacitinib for treating refractory moderate-to-severe ulcerative colitis
por: Nakamura, Masanao, et al.
Publicado: (2022) -
Extraintestinal manifestations at baseline, and the effect of tofacitinib, in patients with moderate to severe ulcerative colitis
por: Rubin, David T., et al.
Publicado: (2021) -
Cost Effectiveness of Tofacitinib for the Treatment of Moderate to Severe Active Ulcerative Colitis in Colombia
por: Gil, Fabio, et al.
Publicado: (2022) -
Tofacitinib Citrate for Ulcerative Keratitis in a Patient with Rheumatoid Arthritis
por: Meadow, Philip B., et al.
Publicado: (2014)